<?xml version="1.0" encoding="UTF-8"?>



<records>

  <record>
    <language>eng</language>
          <publisher>Oriental Scientific Publishing Company</publisher>
        <journalTitle>Biosciences Biotechnology Research Asia</journalTitle>
          <issn>0973-1245</issn>
            <publicationDate>2014-12-28</publicationDate>
    
        <volume>11</volume>
        <issue>3</issue>

 
    <startPage></startPage>
    <endPage></endPage>

	    <publisherRecordId>10223</publisherRecordId>
    <documentType>article</documentType>
    <title language="eng">Simvastatin Modulates Parasitological Response to Sulfadoxine-Pyrimethamine in Acute Uncomplicated Malaria</title>

    <authors>
	 


      <author>
       <name>Ndubuisi N. Nwobodo</name>

 
		
	<affiliationId>1</affiliationId>
      </author>
    

	 


      <author>
       <name>Paul O. Okonkwo</name>


		
	<affiliationId>2</affiliationId>

      </author>
    

	

	


	


	
    </authors>
    
	    <affiliationsList>
	    
		
		<affiliationName affiliationId="1">Department of Pharmacology and Therapeutics, Ebonyi State University, Abakaliki, Nigeria.  </affiliationName>
    

		
		<affiliationName affiliationId="2">Department of Pharmacology and Therapeutics, University of Nigeria.</affiliationName>
    
		
		
		
		
	  </affiliationsList>






    <abstract language="eng">Mutations in parasite enzymes and sub-optimal dosing associated with poor quality drug administration are considered major causes of parasitological resistance to sulfadoxine-pyrimethamine in the treatment of malaria. This study evaluated the effects of simvastatin in modulating parasitological response to sulfadoxine-pyrimethamine in the treatment of malaria. Malaria patients (n=60) diagnosed by thick blood film and confirmed using immunological tests were selected and informed written consent obtained. Patients were categorized into simvastatin plus sulfadoxine-pyrimethamine (test) and sulfadoxine-pyrimethamine alone (control group). The University of Nigeria Teaching Hospital Research Ethics Committee reviewed the proposal and provided ethical clearance certification (NHREC/05/01/2008B). The WHO criteria was adopted in the assessment of parasitological response and patients followed up on days D0, D3, D7, D14 and D28 post-treatment. The analysis of data was done using GraphPad Prism 4.0 and data presented in tabular and graphical forms. Revealed a statistically significant difference in parasitological response (p&lt;0.05) between test and control groups. The mean value of low level resistance, RI was given as 8.5±0.76%, mid-level resistance, RII as 7.7±0.82%, high level parasitological resistance, RIII as 5.2±0.35% and the late parasitological failure, LPF as 3.4±0.29% in the test group. This contrasts with the value of RI given as 17.1±0.61%, RII as 22.6±0.85%, RIII as 15.2±0.76% and the LPF given as 11.4±0.15% in the control group. The implication of present study indicates that the enhanced parasitological response to sulfadoxine-pyrimethamine may be attributed to modulating effects of simvastatin use.</abstract>

    <fullTextUrl format="html">https://www.biotech-asia.org/vol11no3/simvastatin-modulates-parasitological-response-to-sulfadoxine-pyrimethamine-in-acute-uncomplicated-malaria/</fullTextUrl>



      <keywords language="eng">
        <keyword>HMG-CoA reductase inhibitor; Malaria; Parasite resistance; Parasitological response; Plasmodium falciparum; Simvastatin</keyword>
      </keywords>

  </record>
</records>